Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Manshi Yang,Mengying Cui,Yang Sun,Shui Liu,Weibo Jiang

DOI: https://doi.org/10.1186/s12964-024-01711-w

IF: 7.525

2024-06-20

Cell Communication and Signaling

Abstract:Anti-programmed death 1/programmed death ligand 1 (anti-PD-1/PD-L1) antibodies exert significant antitumor effects by overcoming tumor cell immune evasion and reversing T-cell exhaustion. However, the emergence of drug resistance causes most patients to respond poorly to these immune checkpoint inhibitors (ICIs). Studies have shown that insufficient T-cell infiltration, lack of PD-1 expression, deficient interferon signaling, loss of tumor antigen presentation, and abnormal lipid metabolism are all considered to be closely associated with immunotherapy resistance. To address drug resistance in tumor immunotherapy, a lot of research has concentrated on developing combination therapy strategies. Currently, ICIs such as anti-PD-1 /PD-L1 antibody combined with chemotherapy and targeted therapy have been approved for clinical treatment. In this review, we analyze the mechanisms of resistance to anti-PD-1/PD-L1 therapy in terms of the tumor microenvironment, gut microbiota, epigenetic regulation, and co-inhibitory immune checkpoint receptors. We also discuss various promising combination therapeutic strategies to address resistance to anti-PD-1/PD-L1 drugs, including combining these therapies with traditional Chinese medicine, non-coding RNAs, targeted therapy, other ICIs, and personalized cancer vaccines. Moreover, we focus on biomarkers that predict resistance to anti-PD-1/PD-L1 therapy as well as combination therapy efficacy. Finally, we suggest ways to further expand the application of immunotherapy through personalized combination strategies using biomarker systems.

cell biology

What problem does this paper attempt to address?

The problem this paper attempts to address is the issue of drug resistance in cancer treatment with immune checkpoint inhibitors (ICIs). Specifically, although immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have expanded treatment options for many types of cancer, the response of most patients to these therapies is not ideal. Approximately 70% of patients only exhibit a transient T-cell recovery without sustained therapeutic effects. Drug resistance is the main reason for the poor efficacy.

The paper analyzes various mechanisms leading to resistance to anti-PD-1/PD-L1 therapy, including the tumor microenvironment (TME), gut microbiome, epigenetic regulation, and the role of co-inhibitory immune checkpoint receptors. Additionally, the paper discusses various promising combination therapy strategies to overcome resistance to anti-PD-1/PD-L1 drugs, including combinations with traditional Chinese medicine, non-coding RNA, targeted therapy, other immune checkpoint inhibitors, and personalized cancer vaccines. Finally, the paper explores biomarkers for predicting resistance to anti-PD-1/PD-L1 therapy and the effectiveness of combination therapies, and proposes methods to further expand the application of immunotherapy through personalized combination treatment strategies.